Episode 075: Intro to CAR-T, Bispecifics (BiT...

This week, we put everything we talked about in our ITP series together and talk about how we manage ITP in complicated patient scenarios. Through a case-based discussion, we discuss how to we would approach each of these complicated scenarios. If you haven’t done so already, be ...  Show more

This week, we move to the relapsed/refractory ITP setting, focusing on what options are available to patients after their initial treatment with steroids ± IVIg, which we discussed in Episode 155. If you have not done so already, definitely listen to that episode as we build on t ...  Show more

Tune in to our podcast for an in-depth discussion on immunotherapeutic strategies for Acute Myeloid Leukemia (AML). In this episode, we feature Dr Sarah Tettamanti, a senior scientist at the Fondazione Tettamanti Research Centre in Italy, who shares her expertise on CAR T-cell th ...  Show more

Joseph Mikhael, MD, and Krina K. Patel, MD, MSc, discuss considerations for CAR T-Cell therapy in multiple myeloma, including age, access, and bridging therapy. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002715. ...  Show more

This episode examines CAR T-cell therapy’s early successes, broader promise, and emerging risks, as the FDA considers reports of occasional secondary cancers. A full transcript of this episode is available at nejm.org/doi/full/10.1056/NEJMp2400701. 

Send us Fan MailAs a result of the rapid adoption CAR-T therapy for certain lymphoid malignancies and multiple myeloma, of these treatments, CRS and ICANS will become more common in IM wards in the coming years. Take a listen to learn about how to treat this emerging condition. T ...  Show more